Genenta Science (GNTA) grants CFO 80,000 stock options at $0.63

Rhea-AI Filing Summary

Genenta Science S.p.A. reported that Chief Financial Officer Richard B. Slansky received a grant of stock options covering 80,000 American Depositary Shares. The options have an exercise price of $0.63 per share and expire on December 31, 2035.

The award was granted at no cost and is a compensation-related acquisition, not an open-market purchase. According to the footnote, the options vest in equal monthly installments over three years beginning March 30, 2026, and all 80,000 options were reported as held directly following the transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SLANSKY RICHARD B

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	80,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 80,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 80,000 options Exercise price: $0.63 per share Underlying ADS: 80,000 American Depositary Shares +3 more

6 metrics

Options granted 80,000 options Stock Option (right to buy) grant to CFO

Exercise price $0.63 per share Option conversion or exercise price

Underlying ADS 80,000 American Depositary Shares Shares subject to the option award

Expiration date December 31, 2035 Option term end date

Vesting schedule 3 years monthly Equal monthly vesting starting March 30, 2026

Holdings after grant 80,000 derivative securities Total stock options held following transaction

Key Terms

Stock Option (right to buy), American Depositary Shares, vest in equal monthly installments, Chief Financial Officer

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

American Depositary Shares financial

"underlying_security_title: American Depositary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

vest in equal monthly installments financial

"The stock options vest in equal monthly installments over three years"

Chief Financial Officer financial

"officer_title: Chief Financial Officer"

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SLANSKY RICHARD B

(Last) (First) (Middle)

13973 CARRIAGE ROAD

(Street)

POWAY CALIFORNIA 92064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Genenta Science S.p.A. [ GNTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.63	03/30/2026		A		80,000		(1)	12/31/2035	American Depositary Shares	80,000	$0	80,000	D

Explanation of Responses:

1. The stock options vest in equal monthly installments over three years beginning March 30, 2026.

	/s/ Richard B. Slansky	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Genenta Science (GNTA) disclose about its CFO in this Form 4?

Genenta Science disclosed that its Chief Financial Officer, Richard B. Slansky, received a grant of stock options for 80,000 American Depositary Shares at a $0.63 exercise price, expiring December 31, 2035, as part of his compensation.

How many Genenta Science (GNTA) options were granted to the CFO?

The CFO received stock options covering 80,000 American Depositary Shares. These options were granted at no cost on the grant date and represent a derivative, compensation-related award rather than an open-market purchase of Genenta Science stock.

What is the exercise price of the CFO’s Genenta Science (GNTA) stock options?

The stock options granted to the CFO have an exercise price of $0.63 per share. This is the price at which he can buy American Depositary Shares if he exercises the options during the option term.

When do the Genenta Science (GNTA) CFO stock options vest?

According to the filing footnote, the stock options vest in equal monthly installments over three years beginning March 30, 2026. This means the CFO gains the right to exercise a portion of the options each month over that period.

When do the Genenta Science (GNTA) CFO stock options expire?

The stock options granted to the CFO expire on December 31, 2035. After this expiration date, any unexercised options will lapse, and the right to purchase Genenta Science American Depositary Shares under this grant will end.

Is the Genenta Science (GNTA) CFO’s Form 4 transaction a market purchase or a grant?

The transaction is a grant of stock options, not a market purchase. It is reported under code A as a grant, award, or other acquisition, and reflects compensation rather than the CFO buying shares on the open market.